Zongertinib conferred a clinically meaningful benefit in patients with previously treated, advanced, HER2-mutant NSCLC in a phase 1 trial.

Our trial provides proof of concept that cytokine-armored CAR T-cell treatment is feasible and may enhance antitumor activity without additional toxic effects,” researchers reported.

B-cell maturation antigen (BCMA)-directed bispecific antibodies have tolerable safety profiles in frail patients with relapsed/refractory multiple myeloma (MM), according to a real-world study ...